Basic information of Apremilast

Name

Apremilast

Alias

Apremilast (CC-10004)

CAS NO.

608141-41-9

Molecular Formula

C22H24N2O7S

Molecular Weight

460.51

Quality Standard

99% min

Grade Standard

Medicine grade

Package Size

1kg packing

Use of Apremilast

Apremilast was approved by the USFDA in March 2014 for treatment of adults with active psoriatic arthritis. Apremilast is the first oral agent that is FDA-approved for the treatment of psoriatic arthritis and offers the convenience of oral dosing compared to treatment with biopharmaceuticals. In September 2014, the USFDA approved Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis.It is also being tested for its efficacy in treating other chronic inflammatory diseases such as ankylosing spondylitis, Behcet's disease, and rheumatoid arthritis.

MORE_DETAIL Apremilast 608141-41-9

Basic information of Apremilast

Name

Apremilast

Alias

Apremilast (CC-10004)

CAS NO.

608141-41-9

Molecular Formula

C22H24N2O7S

Molecular Weight

460.51

Quality Standard

99% min

Grade Standard

Medicine grade

Package Size

1kg packing

Use of Apremilast

Apremilast was approved by the USFDA in March 2014 for treatment of adults with active psoriatic arthritis. Apremilast is the first oral agent that is FDA-approved for the treatment of psoriatic arthritis and offers the convenience of oral dosing compared to treatment with biopharmaceuticals. In September 2014, the USFDA approved Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis.It is also being tested for its efficacy in treating other chronic inflammatory diseases such as ankylosing spondylitis, Behcet's disease, and rheumatoid arthritis.